ImmunityBio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

ImmunityBio şirketinin toplam hissedar öz sermayesi $-499.6M ve toplam borcu $803.5M olup, bu da borç-öz sermaye oranını -160.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $501.9M ve $1.0B dir.

Anahtar bilgiler

-160.83%

Borç/özkaynak oranı

US$803.46m

Borç

Faiz karşılama oranı	n/a
Nakit	US$242.82m
Eşitlik	-US$499.57m
Toplam yükümlülükler	US$1.00b
Toplam varlıklar	US$501.90m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Mar 17

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

Mar 04Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 07

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 07

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

Dec 11

ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful

Oct 25

ImmunityBio: Moving The Needle

Oct 07

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IBRX negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: IBRX şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IBRX negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: IBRX 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IBRX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: IBRX serbest nakit akışı her yıl % 10.8 2 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/18 00:20
Gün Sonu Hisse Fiyatı	2026/03/18 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza ilişkin kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

ImmunityBio, Inc. 8 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Suranjit Mukherjee	BTIG
Justin Zelin	BTIG
Jason Kolbert	D. Boral Capital LLC.

ImmunityBio Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion

Immunitybio Announces NCCN Clinical Practice Guidelines in Oncology Have Been Updated to Include Anktiva Plus BCG for Patients with BCG-Unresponsive NMIBC with Papillary-Only Disease

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from over 60 Healthy and Cancer Donors

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Forecast breakeven date moved forward to 2027

Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects

ImmunityBio, Inc. Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA®? Plus BCG Versus BCG Alone in BCG-Naive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

President exercised options and sold US$675k worth of stock

New major risk - Financial position

Full year 2025 earnings: EPS exceeds analyst expectations

ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio, Inc. Reports Productive Regulatory Engagement with Saudi Food and Drug Authority At USA -Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

President exercised options and sold US$971k worth of stock

ImmunityBio, Inc. Launches Phase 2 Chemotherapy-FreeCAR-NK Cell Therapy Trial with Anktiva (ResQ215B) in Indolent Lymphomas

ImmunityBio, Inc. Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA Plus CAR-NK, Chemo-Free Therapy

Price target increased by 9.6% to US$11.40

Board Member notifies of intention to sell stock

Immunitybio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

Consensus estimates of losses per share improve by 10%

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

New minor risk - Share price stability

Saudi Fda Grants Accelerated Approval to ImmunityBio , Inc.'s Anktiva for Non-Muscle Invasive Bladder Cancer Witharcinoma In-Situ

ImmunityBio, Inc. Announces Positive Results Demonstrating ANKTIVA as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Forecast to breakeven in 2028

ImmiBio, Inc. Announces Treatment with ANKTIVA®? (nogapendekin Alfa Inbakicept-pmln) Plus Bacillus Calmette-Guerin

ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for Anktiva with Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

New minor risk - Financial position

Third quarter 2025 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

ImmunityBio, Inc. Announces its ANKTIVA Reverses Lymphopenia and Extends Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. Announces Initial Data Shows 100% Disease Control in 5 Out of 5 Patients with Recurrent Glioblastoma with Two Patients in Near Complete Response Treated with Immunotherapy's ANKTIVA®?, NK Cell Therapy Plus Optune Gio®? Device

ImmunityBio, Inc. Announces Phase 2 Study of ANKTIVA®? in Patients with Long COVID

Price target decreased by 16% to US$10.20

Immunitybio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free

ImmunityBio, Inc. Announces Houston's Michael E. DeBakey Department of Veterans Affairs Medical Center Is Among the First VA Hospitals to Helpister ANKTIVA to Bladder Cancer Patients

No longer forecast to breakeven

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Immunitybio, Inc. Receives Fda Expanded Access Authorization for Landmark Treatment of Lymphopenia with Anktiva, the Cancer Bioshield™ Platform, in Patients with Solid Tumors

First quarter 2025 earnings: EPS misses analyst expectations

ImmunityBio, Inc. Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Supplemental Biologics License Application

ImmunityBio, Inc., Annual General Meeting, Jun 18, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

ImmunityBio, Inc. Announces Positive Long-Term Results from Its Quilt-3.032 Study of Anktiva® (Nogapendekin Alfa Inbakicept-Guerin) Plus BCG

New major risk - Shareholder dilution

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia

ImmunityBio, Inc. has filed a Follow-on Equity Offering in the amount of $75.000001 million.

Pomerantz LLP and Holzer & Holzer, LLC Announces Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio, Inc. Announces First Dosing of Recombinant BCG in the U.S. and 60 Sites Are in the Process of Launching

Consensus revenue estimates decrease by 23%, EPS upgraded

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Price target decreased by 7.7% to US$11.25

New minor risk - Shareholder dilution

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ImmunityBio, Inc. Announces Certain Operational Results Following Approval of the Permanent J-Code (J9028) in January 2025

New major risk - Share price stability

ImmunityBio, Inc. Receives FDA RMAT Designation for ANKTIVA and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-Of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

President exercised options and sold US$267k worth of stock

U.S. Food and Drug Administration Authorizes ImmunityBio, Inc. to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

Immunitybio, Inc. Announces Uk Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for Anktiva

John Owen Brennan Resigns as a Member of the Board of Directors and from All Committees of the Board of ImmunityBio, Inc

ImmunityBio, Inc. Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA®? for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio, Inc. Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Immunitybio, Inc. Announces Permanent J-Code (J9028) for Anktiva®? Is Now Effective

Forecast to breakeven in 2027

ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

New major risk - Share price stability

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

ImmunityBio, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates fall by 15%

ImmunityBio, Inc. Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS